Indegene Q1 FY27 earnings call

Indegene reported strong Q1 FY27 revenues of INR 10,631 million, marking a robust 39.7% year-on-year and 6% quarter-on-quarter growth in INR terms. In USD terms, revenue grew 26.5% YoY and 2.5% QoQ, reaching $112.5 million. This performance represents the strongest first-quarter sequential growth in four years. The company's active client base expanded to 105, adding 2 new customers to the $10-$25 million bucket, which now totals 9, indicating a broadening client base and diversified revenue streams, with accounts beyond the top 20 contributing over a third of total revenues.

The EBITDA for Q1 FY27 stood at INR 1,795 million, with a margin of 16.9%. While the reported margin was 50 basis points higher QoQ, adjusting for the prior quarter's mark-to-market impact^🌐, margins declined sequentially. This was attributed to one-time^📎 workforce transformation costs and the slow revenue build-up from certain Gen AI engagements. Management expects margin normalization to the historical range of 19%-20% by Q4 FY27, driven by the ramp-up of signed deals and productivity benefits from Gen AI initiatives.

Indegene continues to invest heavily in its proprietary tech stack and Gen AI capabilities, viewing AI as an accelerant rather than a threat. The company's strategy involves building a data layer, the Cortex platform for knowledge engineering, and an agent layer for specific outcomes like Content Super App and Medical Writing. This embedded approach to AI, honed over a decade, differentiates Indegene by solving customer problems and enhancing efficiency across commercial and medical functions, rather than creating a separate AI business unit.

The quarter saw robust deal wins, including one in the $3-$5 million range and four in the $1-$3 million range. Key wins included the expansion of the Tectonic engagement in Germany to Spain and a top 20 pharma company selecting Indegene for creative and digital production across the U.S. These wins demonstrate the company's ability to move upstream in the value chain, capturing high-value work in conceiving, planning, and building commercial and medical activities, leveraging its differentiated proposition of organic and inorganic capabilities.

Indegene maintains a strong financial position with cash and cash equivalents combined with investments totaling INR 14,602 million. Days Sales Outstanding (DSOs) increased by 4 days QoQ to 67 days. Management expressed low concern regarding client receivables, citing that over 90% of their business comes from Fortune 500/1000 pharma companies with strong balance sheets, and historically, bad debt write-offs have been minimal. The company has also adopted designated hedge accounting to mitigate currency volatility^🌐, ensuring it will no longer impact operating margins.

Indegene anticipates FY27 organic growth to be better than FY26, with an acceleration expected in the second half of the fiscal year. The outcome-based omnichannel engagement, which has incurred costs but deferred revenue recognition, is expected to start contributing to revenue from Q3 FY27, aiding both growth and profitability. The company is confident in its ability to deepen client relationships, convert pipeline into revenue, and bring margins back to the 19%-20% historical levels by Q4 FY27, supported by productivity initiatives and deal ramp-ups.